Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10327380 | 0.89 | HTR6 (0.72) | HTR6ADRA2ARECQLKMT2AMAPT | |
| SCHEMBL2899919 | 0.88 | HTR6 (0.71) | HTR6ADRA2ARECQLKMT2AMAPT | |
| SCHEMBL2901197 | 0.87 | HTR6 (1.00) | HTR6ADRA2ARECQLKMT2AMAPT | |
| SCHEMBL2906976 | 0.85 | HTR6 (0.73) | HTR6ADRA2ARECQLKMT2AMAPT | |
| SCHEMBL10326743 | 0.79 | HTR6 (0.76) | HTR6ADRA2AKMT2AMAPTLMNA | |
| SCHEMBL2906909 | 0.73 | HTR6 (0.53) | HTR6ADRA2ARECQLKMT2AMAPT | |
| SCHEMBL16291482 | 0.73 | RECQL (0.65) | HTR6ADRA2ARECQLKMT2AMAPT | |
| SCHEMBL9942077 | 0.71 | RECQL (0.71) | HTR6RECQLKMT2AMAPTLMNA | |
| SCHEMBL7573136 | 0.71 | KEAP1 (0.76) | RECQLKMT2AMAPTLMNAMEN1 | |
| SCHEMBL2055418 | 0.70 | RECQL (0.69) | HTR6ADRA2ARECQLKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217041-B2 | Indene derivatives, their preparation and use as medicaments | Laboratories del Sr. Esteve, S.A. (ES) | 2012-07-10 | — | — | US | disclosed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR6, HTR5A, HTR1A | HTR6 1/4885ADRA2A 25/4885RECQL 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.